JP2019518052A5 - - Google Patents

Download PDF

Info

Publication number
JP2019518052A5
JP2019518052A5 JP2018565750A JP2018565750A JP2019518052A5 JP 2019518052 A5 JP2019518052 A5 JP 2019518052A5 JP 2018565750 A JP2018565750 A JP 2018565750A JP 2018565750 A JP2018565750 A JP 2018565750A JP 2019518052 A5 JP2019518052 A5 JP 2019518052A5
Authority
JP
Japan
Prior art keywords
diabetes
tumor
treatment
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018565750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518052A (ja
JP6900406B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2017/088030 external-priority patent/WO2017215588A1/zh
Publication of JP2019518052A publication Critical patent/JP2019518052A/ja
Publication of JP2019518052A5 publication Critical patent/JP2019518052A5/ja
Application granted granted Critical
Publication of JP6900406B2 publication Critical patent/JP6900406B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018565750A 2016-06-16 2017-06-13 Akt阻害剤としてのジヒドロピラゾロアゼピン系化合物 Active JP6900406B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610428049.6 2016-06-16
CN201610428049 2016-06-16
CN201610674021.0 2016-08-15
CN201610674021 2016-08-15
PCT/CN2017/088030 WO2017215588A1 (zh) 2016-06-16 2017-06-13 作为Akt抑制剂的二氢吡唑氮杂卓类化合物

Publications (3)

Publication Number Publication Date
JP2019518052A JP2019518052A (ja) 2019-06-27
JP2019518052A5 true JP2019518052A5 (cg-RX-API-DMAC7.html) 2020-05-14
JP6900406B2 JP6900406B2 (ja) 2021-07-07

Family

ID=60663995

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018565750A Active JP6900406B2 (ja) 2016-06-16 2017-06-13 Akt阻害剤としてのジヒドロピラゾロアゼピン系化合物

Country Status (6)

Country Link
US (1) US10654868B2 (cg-RX-API-DMAC7.html)
EP (1) EP3473628B1 (cg-RX-API-DMAC7.html)
JP (1) JP6900406B2 (cg-RX-API-DMAC7.html)
KR (1) KR102351270B1 (cg-RX-API-DMAC7.html)
CN (1) CN109311908B (cg-RX-API-DMAC7.html)
WO (1) WO2017215588A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7101781B2 (ja) * 2017-12-13 2022-07-15 ハルビン チェンバオ ファーマシューティカル カンパニー リミテッド Akt阻害剤としての塩形態及びその結晶形態
CN116583525A (zh) * 2020-12-07 2023-08-11 南京正大天晴制药有限公司 一种吡唑并氮杂卓类akt抑制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887864B2 (en) 2002-03-12 2005-05-03 Hoffmann-La Roche Inc. Azepane derivatives
CN101094833A (zh) * 2004-07-12 2007-12-26 伊邓药品公司 四肽类似物
JP5284973B2 (ja) * 2006-11-28 2013-09-11 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 三環式インドールおよび(4,5−ジヒドロ)インドール
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
EP2002836B1 (en) 2007-05-31 2010-10-20 Nerviano Medical Sciences S.r.l. Cyclocondensed azaindoles active as kinase inhibitors
JP2011509261A (ja) * 2008-01-07 2011-03-24 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連用途向けの化合物
US20110129455A1 (en) 2008-06-26 2011-06-02 Hong Lin Inhibitors of akt activity
EP2640369A1 (en) * 2010-11-17 2013-09-25 F.Hoffmann-La Roche Ag Methods of treating tumors

Similar Documents

Publication Publication Date Title
JP2016518337A5 (cg-RX-API-DMAC7.html)
JP2015147774A5 (cg-RX-API-DMAC7.html)
IL279015A (en) Anti-interleukin-17A antibody, its pharmaceutical preparation and its use
WO2016131067A3 (en) Pharmaceutical compositions comprising meloxicam
JP2016028092A5 (cg-RX-API-DMAC7.html)
IL314347A (en) Combined treatment of lasmiditan and a CGRP antagonist for use in the treatment of migraine
JP2017537928A5 (cg-RX-API-DMAC7.html)
JP2020536085A5 (cg-RX-API-DMAC7.html)
JP2014530840A5 (cg-RX-API-DMAC7.html)
SG11202112111WA (en) Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof
HK1254343A1 (zh) 药物制剂
EP3894398A4 (en) 3,3-DIFLUOROALLYLAMINES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
WO2017062468A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
HUE067057T2 (hu) Gyógyszerkészítmény C5-tel kapcsolatos betegség kezelésében vagy megelõzésében történõ alkalmazásra
JP2017537912A5 (cg-RX-API-DMAC7.html)
CY1123844T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
JP2017197541A5 (cg-RX-API-DMAC7.html)
JP2019518052A5 (cg-RX-API-DMAC7.html)
EP3539978A4 (en) FRAGMENT OF NKX3.2 AND PHARMACEUTICAL COMPOSITION CONSISTING IT AS AN ACTIVE SUBSTANCE
WO2017105881A8 (en) Deuterated compounds for treating pain
PL3778609T3 (pl) Pochodne penamu lub ich sole, kompozycje farmaceutyczne i ich zastosowanie
HK1243709A1 (zh) 可用於治疗阿尔茨海默氏病的四氢呋喃稠合的氨基氢噻嗪衍生物
PL3867244T3 (pl) Pochodne 4-pirazyn-2-ylometylomorfoliny i ich zastosowanie jako lek
JP2019526545A5 (cg-RX-API-DMAC7.html)
EP3623384A4 (en) ANTI-CLDN-5 ANTIBODY AND ACTIVE SUBSTANCE WITH THIS ANTIBODY